Dr. Modest Discusses the German AIO KRK0110 Study in CRC | OncLive

Dr. Modest Discusses the German AIO KRK0110 Study in CRC

August 18, 2017

Dominik P. Modest, MD, University of Munich, discusses the German AIO KRK0110 study in metastatic colorectal cancer.

Dominik P. Modest, MD, University of Munich, discusses the German AIO KRK0110 study in metastatic colorectal cancer (CRC).

AIO KRK0110 is a randomized phase III study of fluoropyrimide plus bevacizumab (Avastin) versus fluoropyrimide plus irinotecan and bevacizumab as first-line therapy for metastatic CRC.

This sequence study aims to answer the question of de-escalation in this patient population.


x